Skip to main content
EQT Logo
Current Portfolio

Exciva

Exciva is a German clinical-stage biotech company developing Deraphan, a combination of dextromethorphan and deramciclane, for the treatment of agitation in Alzheimer’s Disease (AD).

Key Facts
Sector

Life Sciences

Country

Germany

Fund

LSP Dementia Fund

Entry

2025

Website

Exciva

Responsible Partner

Philip Scheltens

Philip Scheltens

Partner and Head of Dementia Fund

About

Do you want to know more about investing with EQT?

We are eager to explore how we can achieve great things together.

Exciva | EQT Portfolio